Tailor-Made vaccine aims to stop cancer return in High-Risk patients
NCT ID NCT07504484
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested a personalized immunotherapy (iNeo-Vac-P01) in 6 patients with stage III colorectal or non-small cell lung cancer who had already completed surgery and standard adjuvant therapy. The vaccine was designed to target unique neoantigens from each patient's tumor, aiming to activate the immune system to eliminate any remaining cancer cells and prevent recurrence. The main goals were to check safety and see if the approach could improve recurrence-free survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- personalized neoantigen peptides plus GM-CSF
- What this could lead to
- If it works, this could lead to a personalized vaccine that helps prevent cancer from coming back after surgery and standard therapy.
- What could go wrong
- This was a very small, early-phase trial with only 6 participants, so results may not apply to everyone. The treatment is complex and tailored to each person, making it hard to scale.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CRC (COLORECTAL CANCER) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
2nd Affiliated Hospital, School of Medicine, Zhejiang University, China
Hangzhou, Zhejiang, 310009, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a four-pronged attack shrink liver tumors enough for surgery?
- Can a Two-Pronged antibody boost chemo against Hard-to-Treat colorectal cancer?
- New drug cocktail aims to shrink Hard-to-Treat colorectal tumors
- Real-World data on colorectal cancer: what happens to patients over time?
- Engineered immune cells take on Hard-to-Treat colorectal cancer
- AI aims to improve colon polyp measurement for cancer prevention